Cognizant (CTSH) Q3 2026 Earnings Call Transcript

Cognizant reported Q3 revenue of $5.7B, up 4.8% year over year in constant currency, adjusted operating margin of 16.3% (up 30 bps), and adjusted EPS of $1.49 (up 7.2%). It narrowed full-year revenue growth guidance to 4.0%-4.4% from 4.0%-5.5% previously, citing greater-than-expected macro pressure on health care and consumer-facing discretionary spending, while narrowing adjusted EPS guidance to $5.72-$5.79, or 8%-10% growth. AI investment and bookings offered support, including 4% growth in trailing-12-month bookings, a 1.3 book-to-bill ratio, and about $200M of expected 2026 Project Leap savings; the company returned $2.3B to shareholders year to date.

Analysis

CTSH’s key upside is not simply AI demand; it is whether the company can retain the productivity dividend as delivery shifts from labor hours toward fixed-price, transaction-based and platform work. The rising fixed-price mix creates operating leverage if Cognizant delivers faster with AI and holds contract economics. But it also transfers execution risk to the vendor: aggressive repricing or client demands to share savings could turn AI-assisted delivery into revenue cannibalization rather than margin expansion. The call does not yet establish realized AI-related revenue or pricing power; certifications and assisted-development penetration are inputs, not proof of monetization.

Near term, the guidance trim and expected higher Q4 furloughs cap the clean-earnings narrative. The 1.3 book-to-bill and stronger new/expansion mix are constructive, but longer contract terms and lower trailing ACV temper the inference that bookings convert quickly. Watch organic growth separately from acquisition contribution, especially in 2027. Health-care recovery is conditional on funding/regulatory clarity, not secured; consumer-facing demand remains macro-sensitive. DSO deterioration is a small but relevant counterpoint to strong reported free cash flow and capital returns.

Over 6–18 months, Cognizant may gain share in legacy modernization, cyber remediation and bounded operations, while traditional labor-arbitrage providers face pressure to match AI-enabled productivity. Google Cloud and CrowdStrike may benefit from expanded enterprise deployments, but Cognizant’s ability to capture economics versus platform partners is unproven. Contrarian risk: investors may be treating broad AI enthusiasm as a durable services-growth catalyst before client budgets and outcome-based pricing validate it.

Key Decisions for Investors

• CTSH: maintain a constructive but measured bias; prefer adding on weakness over chasing the earnings reaction. Reassess after Q4 results and initial 2027 guidance, focusing on organic constant-currency growth and margin progression.
• Treat AI monetization as a confirmation trade, not a certification-count story: monitor fixed-price/transaction mix, realized revenue per associate, gross margin, and evidence that clients accept outcome-based pricing without equivalent rate compression.
• Watch the gap between reported growth and organic growth, plus trailing ACV versus bookings. If new-business mix fails to translate into organic acceleration by early 2027, the growth thesis weakens; deterioration in margins alongside AI investment would further falsify operating leverage.
• Do not extrapolate the health-care rebound management anticipates. Track Medicaid/Medicare funding and enrollment developments; continued discretionary weakness or another guidance reduction would be a catalyst to reduce exposure.
• GOOG and CrowdStrike are potential ecosystem beneficiaries, but the call provides no quantified incremental economics for either. Avoid treating the partnership announcements as standalone earnings catalysts without disclosed revenue or deal-conversion evidence.